Literature DB >> 11096147

Intervention thresholds and ceilings can determine the haemoglobin outcome distribution in a haemodialysis population.

D Richardson1, C Bartlett, E J Will.   

Abstract

We have explored the consequences of setting different thresholds and ceilings for erythropoietin dose changes in two randomized controlled studies of renal anaemia management based on an established algorithm. STUDY 1: A large (n=236) unselected haemodialysis cohort was randomized to monthly intervention (increased erythropoietin (Epo)) at haemoglobin (Hb) levels falling below either 10.5 g/dl (group A) or 11.5 g/dl (group B) and followed for 6 months. The mean Hb was 0.6 g/dl higher in the 11.5 g/dl threshold group (11.1 g/dl vs 11.7 g/dl) at 6 months (P=0.001++). The Epo dose did not differ between them (median 133 IU/kg/week, Interquartile range (IQR) 86-217 and 140, IQR 74-227 respectively) (P=NS(**)). STUDY 2: A large (n=211) unselected haemodialysis cohort was randomized to a reduction in Epo dose at Hb levels above either 12.0 g/dl (group C) or 13.0 g/dl (group D). The Hb outcome at 8 months differed between group C (mean 11.5 g/dl, SD 1.4) and group D (12.2, SD 2.1) (P=0.03++). The Epo dose did not significantly differ between groups C and D (median 60 IU/kg/week, IQR 32-142 and 71, IQR 38-117 respectively) (P=NS(**)). Study 1 showed that an intervention threshold of 11.0 g/dl with a mean Hb outcome of 11.6 g/dl and SD 1.6 g/dl would produce the desired UK Renal Association Standards outcome of 85% Hb > or =10.0 g/dl. Study 2 demonstrated that a ceiling of 12.0 g/dl narrowed the range of Hb values (P:<0.001##), achieving a SD of 1.37 g/dl, and reduced the number of patients with a Hb >13.0 g/dl from 25 to 12%. This narrowing of the distribution has cost implications for reaching minimum standards in a haemodialysis population. Formal use of threshold and ceiling values for intervention within an anaemia management system enabled the haemodialysis population outcome mean and SD to be literally prescribed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11096147     DOI: 10.1093/ndt/15.12.2007

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

1.  Aiming at averages.

Authors:  E J Will
Journal:  J R Soc Med       Date:  2001-12       Impact factor: 5.344

2.  Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis.

Authors:  Juan José Pérez-Ruixo; Mercedes Cucala-Ramos; Ester García-Gonzalo; Beatriz Del Val Romero; Neus Valveny
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

3.  Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness?

Authors:  Luca Gabutti; Nathalie Lötscher; Josephine Bianda; Claudio Marone; Giorgio Mombelli; Michel Burnier
Journal:  BMC Nephrol       Date:  2006-09-18       Impact factor: 2.388

4.  Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness.

Authors:  Angel L M de Francisco; Peter Stenvinkel; Sophie Vaulont
Journal:  NDT Plus       Date:  2009-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.